Evidence that local administration of IFNα-MSCs contributed to a systemic anti-tumor effect was provided by the increase in CD44+CD62L+ CD8+ T cells in tumor draining lymph node observed in tumors injected with IFNα-MSCs. The gene discussed is CD44; the disease is neoplasm.